WCLC 2025 - Posters & ePosters-P3.12.26 Adding Gefitinib to Target Acquired C797S Mutation After Progression on First-Line Osimertinib in EGFR-Mutant Advanced NSCLC

P3.12.26 Adding Gefitinib to Target Acquired C797S Mutation After Progression on First-Line Osimertinib in EGFR-Mutant Advanced NSCLC

Asset Subtitle

Zi-Ji Mao

Meta Tag

Speaker Zi-Ji Mao

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy